GSK Ends Hepatitis B Drug Trial After FDA Approval
The company terminated its Phase 1 study for a drug candidate following the regulatory clearance of a new treatment.
Updated on Oct. 21, 2026 in Biotech
Live Poll
Should pharmaceutical companies focus solely on proven drug approvals rather than pursuing risky experimental therapies?
GSK has officially ended its Phase 1 clinical trial for the drug candidate GSK3965193, a PAPD5/PAPD7 inhibitor. This decision follows the FDA's recent approval of the company's hepatitis B medication, bepirovirsen.
Why it matters
The move reflects a strategic consolidation of the company pipeline as it shifts focus toward its newly approved therapeutic, Hibsago. The transition marks a pivot away from earlier-stage candidates in favor of products cleared for commercial use.
GSK3965193, which began Phase 1 testing in 2022, was designed as a PAPD5/PAPD7 inhibitor for hepatitis B treatment. The company currently maintains its focus on GSK5637608, which remains in Phase 2 development.
The players
GSK
This British multinational pharmaceutical and biotechnology company develops and manufactures vaccines, medicines, and consumer healthcare products.
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of human and veterinary drugs.
The details
GSK updated its federal clinical trials registry to confirm the termination of the GSK3965193 program. The company previously halted the development of another candidate, the TLR8 agonist GSK5251738, as it streamlines its pharmaceutical portfolio.
Timeline
The Phase 1 study of GSK3965193 began in 2022.
The FDA approved bepirovirsen on October 20, 2026.
The termination of the clinical trial was confirmed on October 21, 2026.
The Tech Race
Pharmaceutical firms frequently adjust R&D pipelines to prioritize high-potential assets that have successfully navigated the FDA drug approval process. This streamlining helps companies compete more effectively against rivals by concentrating capital on late-stage, viable technologies.
Adults with chronic hepatitis B without cirrhosis will soon have access to Hibsago, the newly approved treatment from GSK. This regulatory milestone provides a new therapeutic option for patients currently managing the condition.
The takeaway
Pharmaceutical companies often recalibrate their research focus once a core therapy reaches the market. Patients and providers should monitor updates from drug manufacturers as pipeline changes often precede the rollout of new treatments.
Further reading
For additional context on drug development trends, see the Biotech section.
Source note: This article includes information reported by FierceBiotech - free daily biotech briefing.
Live Poll
Should pharmaceutical companies focus solely on proven drug approvals rather than pursuing risky experimental therapies?
